AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 288: H2111-H2117, 2005. First published December 30, 2004; doi:10.1152/ajpheart.00838.2004
0363-6135/05 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
288/5/H2111    most recent
00838.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (19)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mendez, M.
Right arrow Articles by LaPointe, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mendez, M.
Right arrow Articles by LaPointe, M. C.

PGE2-induced hypertrophy of cardiac myocytes involves EP4 receptor-dependent activation of p42/44 MAPK and EGFR transactivation

Mariela Mendez and Margot C. LaPointe

Hypertension and Vascular Research Division, Department of Medicine, Henry Ford Hospital, Detroit, Michigan

Submitted 18 August 2004 ; accepted in final form 22 December 2004

Upon induction of cyclooxygenase-2 (COX-2), neonatal ventricular myocytes (VMs) mainly synthesize prostaglandin E2 (PGE2). The biological effects of PGE2 are mediated through four different G protein-coupled receptor (GPCR) subtypes (EP1–4). We have previously shown that PGE2 stimulates cAMP production and induces hypertrophy of VMs. Because the EP4 receptor is coupled to adenylate cyclase and increases in cAMP, we hypothesized that PGE2 induces hypertrophic growth of cardiac myocytes through a signaling cascade that involves EP4-cAMP and activation of protein kinase A (PKA). To test this, we used primary cultures of VMs and measured [3H]leucine incorporation into total protein. An EP4 antagonist was able to partially block PGE2 induction of protein synthesis and prevent PGE2-dependent increases in cell surface area and activity of the atrial natriuretic factor promoter, which are two other indicators of hypertrophic growth. Surprisingly, a PKA inhibitor had no effect. In other cell types, G protein-coupled receptor activation has been shown to transactivate the epidermal growth factor receptor (EGFR) and result in p42/44 mitogen-activated protein kinase (MAPK) activation and cell growth. Immunoprecipitation of myocyte lysates demonstrated that the EGFR was rapidly phosphorylated by PGE2 in VMs, and the EP4 antagonist blocked this. In addition, the selective EGFR inhibitor AG-1478 completely blocked PGE2-induced protein synthesis. We also found that PGE2 rapidly phosphorylated p42/44 MAPK, which was inhibited by the EP4 antagonist and by AG-1478. Finally, the p42/44 MAPK inhibitor PD-98053 (25 µmol/l) blocked PGE2-induced protein synthesis. Altogether, we believe these are the first data to suggest that PGE2 induces protein synthesis in cardiac myocytes in part via activation of the EP4 receptor and subsequent activation of p42/44 MAPK. Activation of p42/44 MAPK is independent of the common cAMP-PKA pathway and involves EP4-dependent transactivation of EGFR.

prostaglandin E2; epidermal growth factor receptor; cyclooxygenase; G protein; ventricular myocyte; mitogen-activated protein kinase



Address for reprint requests and other correspondence: M. C. LaPointe, Hypertension and Vascular Research Division, Henry Ford Hospital, 2799 West Grand Blvd., Detroit, MI 48202-2689 (E-mail: mlapoin1{at}hfhs.org)




This article has been cited by other articles:


Home page
CirculationHome page
N. Degousee, S. Fazel, D. Angoulvant, E. Stefanski, S.-C. Pawelzik, M. Korotkova, S. Arab, P. Liu, T. F. Lindsay, S. Zhuo, et al.
Microsomal Prostaglandin E2 Synthase-1 Deletion Leads to Adverse Left Ventricular Remodeling After Myocardial Infarction
Circulation, April 1, 2008; 117(13): 1701 - 1710.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
Z. Yin, G. N. Jones, W. H. Towns II, X. Zhang, E. D. Abel, P. F. Binkley, D. Jarjoura, and L. S. Kirschner
Heart-Specific Ablation of Prkar1a Causes Failure of Heart Development and Myxomagenesis
Circulation, March 18, 2008; 117(11): 1414 - 1422.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
M. V. Arcidiacono, T. Sato, D. Alvarez-Hernandez, J. Yang, M. Tokumoto, I. Gonzalez-Suarez, Y. Lu, Y. Tominaga, J. Cannata-Andia, E. Slatopolsky, et al.
EGFR Activation Increases Parathyroid Hyperplasia and Calcitriol Resistance in Kidney Disease
J. Am. Soc. Nephrol., February 1, 2008; 19(2): 310 - 320.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J.-Y. Qian, P. Harding, Y. Liu, E. Shesely, X.-P. Yang, and M. C. LaPointe
Reduced Cardiac Remodeling and Function in Cardiac-Specific EP4 Receptor Knockout Mice With Myocardial Infarction
Hypertension, February 1, 2008; 51(2): 560 - 566.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
M. Testa, B. Rocca, L. Spath, F. O. Ranelletti, G. Petrucci, G. Ciabattoni, F. Naro, S. Schiaffino, M. Volpe, and C. Reggiani
Expression and activity of cyclooxygenase isoforms in skeletal muscles and myocardium of humans and rodents
J Appl Physiol, October 1, 2007; 103(4): 1412 - 1418.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
R. Hatazawa, A. Tanaka, M. Tanigami, K. Amagase, S. Kato, Y. Ashida, and K. Takeuchi
Cyclooxygenase-2/prostaglandin E2 accelerates the healing of gastric ulcers via EP4 receptors
Am J Physiol Gastrointest Liver Physiol, October 1, 2007; 293(4): G788 - G797.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
M. M. Bamman
Take two NSAIDs and call on your satellite cells in the morning
J Appl Physiol, August 1, 2007; 103(2): 415 - 416.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Z. Guo, Z. Xia, J. Jiang, and J. H. McNeill
Downregulation of NADPH oxidase, antioxidant enzymes, and inflammatory markers in the heart of streptozotocin-induced diabetic rats by N-acetyl-L-cysteine
Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1728 - H1736.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. C. Schaub and M. A. Hefti
The PGE2-Stat3 connection in cardiac hypertrophy
Cardiovasc Res, January 1, 2007; 73(1): 3 - 5.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. A. Frias, M. C. Rebsamen, C. Gerber-Wicht, and U. Lang
Prostaglandin E2 activates Stat3 in neonatal rat ventricular cardiomyocytes: A role in cardiac hypertrophy
Cardiovasc Res, January 1, 2007; 73(1): 57 - 65.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J.-Y. Qian, A. Leung, P. Harding, and M. C. LaPointe
PGE2 stimulates human brain natriuretic peptide expression via EP4 and p42/44 MAPK
Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1740 - H1746.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.